Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Amgen Ventures
AddedMar 19, 2024
UpdatedJul 5, 2026
Amgen Ventures

Amgen Ventures

Operating

Global biopharmaceutical innovator developing medicines for serious illnesses.

Location
Thousand Oaks, CA, US
Founded
2004
Firm
Compare
Portfolio
Fundraising
Employees

Investments

Quantinuum
Quantinuum
Public

Total Raised

$325M

Rounds

2

Series Unknown$300MJanuary 2024
Seismic Therapeutic
Seismic Therapeutic

Total Raised

$222M

Rounds

2

Series B$121MDecember 2023
Culmination Bio
Culmination Bio

Total Raised

$10M

Rounds

1

Series A$10MNovember 2023
TileDB
TileDB

Total Raised

$57.3M

Rounds

7

Series B$34MSeptember 2023
Series UnknownMay 2022
ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$50MSeptember 2023
Series B$120MJune 2022
Generate Biomedicines
Generate Biomedicines

Total Raised

$693M

Rounds

3

Series C$273MSeptember 2023
QurAlis
QurAlis

Total Raised

$135.5M

Rounds

4

Series B$88MMarch 2023
Casma Therapeutics
Casma Therapeutics

Total Raised

$154.9M

Rounds

4

Series C$46MNovember 2022
BigHat Biosciences
BigHat Biosciences

Total Raised

$99.3M

Rounds

4

Series B$75MJuly 2022
Kernal Biologics
Kernal Biologics
Series A

Total Raised

$25.1M

Rounds

5

Series A$25MJuly 2022
Senti Biosciences
Senti Biosciences
Public

Total Raised

$215.9M

Rounds

11

Post Ipo Equity$50.6MJune 2022
Series B$105MJanuary 2021
Code Biotherapeutics
Code Biotherapeutics

Total Raised

$85M

Rounds

2

Series A$75MJune 2022
Celsius Therapeutics
Celsius Therapeutics

Total Raised

$148M

Rounds

2

Series B$83MMarch 2022
CancerIQ
CancerIQ

Total Raised

$20M

Rounds

7

Series B$14MMarch 2022
Accure Health
Accure Health

Total Raised

$3.4M

Rounds

6

Non Equity AssistanceMarch 2022
Obsidian Therapeutics
Obsidian Therapeutics

Total Raised

$164.5M

Rounds

2

Series B$115MSeptember 2021
Genome Medical
Genome Medical

Total Raised

$120.4M

Rounds

6

Series C$60MAugust 2021
Catena Biosciences
Catena Biosciences

Total Raised

$5.7M

Rounds

2

Seed$5MAugust 2021
GPB Scientific
GPB Scientific

Total Raised

$57.4M

Rounds

11

Series Unknown$18MMay 2021
Carmot Therapeutics
Carmot Therapeutics

Total Raised

$384.8M

Rounds

8

Series C$47MSeptember 2020
BeOne Medicines
BeOne Medicines
Public

Total Raised

$6.8B

Rounds

8

Post Ipo Equity$2.1BJuly 2020
Syapse
Syapse
Public

Total Raised

$222.6M

Rounds

9

Series F$30MMay 2020